Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gloria Pharma Invests $40 Million in Proteus Digital Health; Gains Option for China JV

publication date: Feb 29, 2016
Gloria Pharma of Harbin, China will invest $40 million in Proteus Digital Health, a US company with a remote patient monitoring device. As a sweetener for the investment, Gloria will have an exclusive 18-month option to form a China JV with Proteus. Proteus expects to raise a total of $110 million in its current H funding round. Gloria will purchase $25 million of Proteus' preferred stock, and will invest another $15 million through Shanghai Sailing Boda Equity Investment Fund Partnership. More details....

Stock Symbol: (SHZ: 2437)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital